Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
FutureChem Co.,Ltd is a South Korean company dedicated to the creation and distribution of radiopharmaceutical products. Its current offerings include PDVUE, a positron emission tomography (PET) diagnostic agent for Parkinson's disease; Alzavue, used in the diagnosis of Alzheimer's disease; and [18F]FDG, a PET radiopharmaceutical primarily employed in cancer therapy. The company's development pipeline is robust, featuring 18F-FC303, a PET diagnostic for prostate cancer; 177Lu-FC705, targeting prostate cancer treatment; 18F-FMT, aimed at brain tumors; 18F-FC505, designed for atherosclerotic plaque; and 18F-FC211, another prospective treatment for Alzheimer's disease. Founded in 1999, FutureChem Co.,Ltd is headquartered in Seoul, South Korea.
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers.